PATIENT IDENTIFICATION CHALLENGE; TANZANIA
PROVEN INTERVENTION TO BE DISTRIBUTED
Cervical cancer screenings.
Learn more about the Patient Identification Challenge and why identifying individuals in need of treatment suffering from health conditions such as obstetric fistula, cervical cancer, clubfoot, and cataracts which can be corrected with cost-effective interventions, could save lives.
DISTRIBUTION MODEL INNOVATION
Con-Com will utilize the network of home based care workers (HBCs) who currently work on HIV treatment to help ensure that more women living in rural areas are screened for cervical cancer. HBCs will alert women to screening services, including on days when the cervical cancer team travels on outreach to villages, and refer patients to screening services. HBCs will also distribute stipends covering transportation fees for women to enure they can reach screening services. Finally, HBCs will help overcome gender barriers by having a male HBC explain the value of screening to men to encourage husbands to support wives when they are screened.
Con-Com will implement their intervention at Shirati Hospital, a district hospital serving over 250,000 people, and located five hours from the nearest referral hospital in Mwanza, Tanzania. Poverty and distance mean that women often do not hear about the screening services available at Shirati Hospital or cannot afford the cost of transport. Con-Com will focus on providing awareness of the benefits and screening and treatment, a stipend to pay for transport to screening services, and assistance in convincing their husband's to allow patients to receive treatment. Additionally, patients are in need of checkups post procedure if they start presenting symptoms. HBCs working with Con-Com will also take on this role.
PILOT AND SCALING GOALS
120 women screened during the pilot
3 women referred to the referral hospital for treatment during the pilot
360 women screened by the end of year 1
600 women screened by the end of year 2
60 women referred to the referral hospital for treatment by the end of year 2
FOUNDING TEAM
Luke Maillie - Founder